Platinum-based anticancer drugs still play a crucial role in the treatment of various solid tumors such as ovarian, lung, colorectal, bladder, and breast cancer. However, their ability to cause dose-dependent systemic toxicity in patients and their inherent resistance problems in practical applications seriously hamper their clinical use. Therefore, it is still necessary to develop more platinum-based anticancer drugs to overcome these obstacles. Among them, platinum(IV) complexes, which break through the structure of cisplatin analogs with low spin d and an octahedral six-coordinated structure, effectively reduce toxicity due to their more inert chemical properties. Additionally, their modifiability allows for the rational design of multifunctionality that cisplatin analogs cannot achieve. Moreover, the continuous innovation of modern nanobiotechnology makes targeted delivery and the multi-drug and multi-mode combination therapy of platinum drugs possible. In particular, the combination of Pt(IV) complexes with nanocarriers is more promising due to their modifiability, providing a novel approach to reducing the adverse reaction caused by traditional platinum drugs, overcoming resistance, and enhancing therapeutic efficacy. In recent years, numerous nanoscale drug delivery systems with good biocompatibility, high drug-loading capacity, and accurate targeting have been developed. Based on our group’s relevant overview published in 2020, this review focuses on appropriate supplements of the nanoscale delivery systems of Pt(IV) complexes and their updates for nearly four years.

中文翻译：

---

铂（IV）抗肿瘤前药纳米级输送系统的最新进展

铂类抗癌药物在卵巢癌、肺癌、结直肠癌、膀胱癌、乳腺癌等多种实体瘤的治疗中仍然发挥着至关重要的作用。然而，它们对患者造成剂量依赖性全身毒性的能力以及在实际应用中固有的耐药性问题严重阻碍了它们的临床使用。因此，仍有必要开发更多的铂类抗癌药物来克服这些障碍。其中，铂(IV)配合物突破了顺铂类似物低自旋d和八面体六配位结构的结构，由于其更惰性的化学性质，有效降低毒性。此外，它们的可修改性允许合理设计顺铂类似物无法实现的多功能性。而且，现代纳米生物技术的不断创新，使得铂类药物的靶向递送和多药多模式联合治疗成为可能。特别是Pt(IV)配合物与纳米载体的结合由于其可修饰性而更具前景，为减少传统铂类药物引起的不良反应、克服耐药性、提高疗效提供了一种新的途径。近年来，众多具有良好生物相容性、高载药量、精准靶向的纳米药物递送系统被开发出来。基于本课题组2020年发表的相关综述，本综述重点关注Pt(IV)配合物纳米级输送系统的适当补充及其近四年来的更新。